SVP, Oncology Therapeutic Area Head
ExternalPrepare for this interview
EliteAI-generated questions, company research, and talking points tailored to this role
About the role
Reporting to the Chief Medical Officer, or CMO, the SVP Oncology Therapeutic Area Head, or TA Head, will be responsible for overseeing the successful development of multiple molecules for the treatment of cancer in Vir Biotechnology's oncology portfolio. The Oncology TA Head will lead the oncology strategy and lead a cross-functional clinical team to develop novel therapeutics from IND through marketing application and registration. This will include guidance and oversight of clinical development strategies for multiple programs and provision of expert input to clinical developability of pre-clinical assets in the oncology pipeline. The TA head will be a key partner for the Research Organization and will provide clinical and strategic leadership for programs in Discovery through IND filing. The TA Head will also be a key partner for business development in oncology. This role is located at Vir Bio's San Francisco headquarters with an expectation of 3 days per week in the office.
Responsibilities
- Lead Vir Bio's Oncology clinical development strategy to deliver registrational data to health authorities for evaluation and, ultimately, to patients and the oncologists who care for them.
- Oversee activities to ensure appropriate objectives and resources are deployed to deliver on key milestones to advance the company's oncology assets in development.
- Coach and mentor program team leaders, clinical scientists and medical monitors.
- Collaborate with Regulatory Sciences to shape the regulatory strategy for oncology clinical development programs and play a key role in representing the Company in health authority interactions
- Core member of the CMO Organization Leadership Team
- Responsible for collaborating with stakeholders across Vir Bio and with external partners, including potential joint development steering committees, to shape the strategy and efficient advancement of molecules throughout clinical development.
- At major congresses, and as needed, represent the Company and the science to various internal and external stakeholders (including the Board of Directors, clinical investigators, KOLs, patient advocacy groups, investors, and analysts).
- WHO YOU ARE AND WHAT YOU BRING
- M.D. with specialty training in Oncology required
- Minimum 12+ years of experience in early and late-stage clinical development at biotech or pharmaceutical company required
- Demonstrated track record applying strategic context to development planning, ability to balance risk and make trade-offs to advance the portfolio priorities
- A high degree of business acumen, a big-picture perspective, and the ability to galvanize a team around a common goal
- Demonstrated track record of accountability, scientific rigor, and innovation
- Ability to build teams and a culture that nourishes creativity, scientific curiosity, with integrity and respect across functions and layers within the Company
- An outcome-driven mindset and a commitment to achieving key milestones
- Exceptional interpersonal and communication skills able to clearly convey complex medical and scientific information to a wide range of internal and external audien
- #LI-AS1
- #LI-Onsite
- WHO WE ARE AND WHAT WE OFFER
- Applicants must currently be authorized to work for any employer in the U.S. We are unable to sponsor or take
Benefits
Additional Information
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN ® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology has exclusive rights to the universal PRO-XTEN ® masking platform for oncology and infectious disease. PRO-XTEN ® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company. We believe the success of our colleagues drives the success of our mission. We are committed to creating a company where everyone feels supported and encouraged to give their best.
Your Match
How well this role fits your profile.
Company Intel
What employees say
Worked at virbiotechnologyinc? Share your experience